Insight

Sam Klempner: DKN-01 with Tislelizumab and Chemotherapy in Advanced Gastric or GEJ Adenocarcinoma

Photo taken from medscape.com

Oct 23, 2024, 14:18

Sam Klempner: DKN-01 with Tislelizumab and Chemotherapy in Advanced Gastric or GEJ Adenocarcinoma

Sam Klempner, Associate Professor at Harvard Medical School, shared on X:

“Adding to the ever growing approaches in GEA

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or GEJ Adenocarcinoma: DisTinGuish.”

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish

Authors: Samuel J. Klempner, Mohamad Bassam Sonbol, Zev A. Wainberg, Hope Elizabeth Uronis, Vi K. Chiu, Aaron James Scott, Syma Iqbal, Mohamedtaki Abdulaziz Tejani, Vincent Chung, Melissa C. Stilian, Mathis Thoma, Ying Zhang, Michael H. Kagey, Jason Baum, Cynthia A. Sirard, Rachel A. Altura, Jaffer A. Ajani.

Sam Klempner

Aaron James Scott cancer Cynthia A. Sirard gastric cancer GEJ adenocarcinoma Hope Elizabeth Uronis Jaffer A Ajani Jason Baum Mathis Thoma Melissa C. Stilian Michael H. Kagey Mohamad Bassam Sonbol Mohamedtaki Abdulaziz Tejani OncoDaily Oncology Rachel A. Altura Sam Klempner Samuel J Klempner Syma Iqbal Tislelizumab Vi K. Chiu Vincent Chung Ying Zhang Zev A. Wainberg

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology